Key clinical point: Patients with NMOSD who receive treatment with satralizumab are less likely to have a severe relapse, compared with controls.
Major finding: The proportion of severe relapses was 19% in the satralizumab group and 35% in the placebo group.
Study details: A pooled intention-to-treat analysis of data for 178 participants in two studies.
Disclosures: Chugai/Roche funded the study. Dr. Kleiter has received compensation for consulting, speaking, or serving on advisory boards for Alexion, Biogen, Celgene, Merck, and Roche.
Kleiter I, et al. MSVirtual2020. Abstract FC01.03.